Illumina Expands World’s Largest Genomics Analysis Platform and Adds to Open Source Initiative
October 01 2015 - 6:30AM
Business Wire
BaseSpace® Professional and Enterprise Packages
Enable Labs to Drive Genomics Innovation and Accelerate Digital
Computing
Illumina, Inc. (NASDAQ: ILMN) today announced several new
additions to BaseSpace—the world’s largest and most comprehensive
cloud computing environment—with the launch of BaseSpace
Professional and Enterprise Editions, fully integrated Laboratory
Information Management System (LIMS) solutions and advanced
infrastructure upgrades.
“BaseSpace is continuing to show phenomenal growth with more
than 75 percent year-over-year growth in new users and more than
900 percent year-over-year growth in app usage,” said Sanjay
Chikarmane, Senior Vice President and General Manager of Illumina’s
Enterprise Informatics. “The new Professional and Enterprise
packages and infrastructure upgrades will provide the industry’s
broadest, most advanced genomics analysis platform. Customers will
have the speed and flexibility to manage their sequencing workflow
on the cloud, reducing infrastructure cost, while accelerating
basic and translational research, eventually leading to improved
clinical care.”
BaseSpace is the only genomics platform that integrates sample
set-up, instrument and sequencing run monitoring along with
storage, analysis and sharing of large volumes of genomic data. The
analysis platform is currently processing data from more than 4,000
sequencing systems worldwide, including Illumina’s population-scale
sequencing system, HiSeq X™ Ten, and providing push-button
analytics with over 60 apps to more than 30,000 registered
users.
Genomic researchers will be able to select from advanced
services that are optimized to enhance the user experience and
improve efficiency in sequencing labs. BaseSpace Professional will
provide multi-user access and automated app launch. BaseSpace
Enterprise adds greater security and convenience through individual
domains, multiple-users and groups, and single sign-on. The
Enterprise edition will also have optional integration with LIMS
solutions from GenoLogics, which was acquired by Illumina in August
2015, leading to improved efficiency and productivity in
laboratories with high throughput.
“The integration of the leading cloud-based genomics laboratory
information management system, Clarity LIMS, with the leading
cloud-based analysis and storage platform, BaseSpace is a natural
fit,” said Michael Ball, Vice President of GenoLogics at Illumina.
"Bringing the two together provides a seamless sample to answer
solution for customers."
“We’ve been impressed with the flexibility of BaseSpace to
handle data from all of the Illumina platforms, including the HiSeq
X system. The ability to upload, store and analyze large-scale
genomic information and share it to a cloud in real time has been a
tremendous benefit to our operation,” said Shawn Levy, PhD.,
Director of the high-volume Genomic Services Laboratory at the
HudsonAlpha Institute for Biotechnology in Huntsville, Ala.
“BaseSpace’s suite of tools, robust infrastructure, and diverse
analysis features allow us to share projects and data across a
broad diversity of projects from around the world.”
BaseSpace is also releasing an update for its on-premise
solution, BaseSpace Onsite. BaseSpace Onsite v2.1 will support more
systems from Illumina’s broad range of sequencing platforms, the
MiSeq®, NextSeq® and HiSeq 2500/3000/4000. The new release offers
more onboard informatics analysis support with 25 apps and a
recently updated version of the BaseSpace platform. BaseSpace
Onsite v2.1 provides push-button informatics to users who are not
yet ready to use BaseSpace in the cloud, or prefer to augment their
bioinformatics team’s capability by offering self-service
informatics analysis with a faster turnaround time.
While adding features to the BaseSpace platform, Illumina is
also continuing its commitment to the open source community by
offering its secondary analysis software under GPL v3 license,
allowing users to run, share and modify the software. Currently,
genomics software that are available under the license agreement
include the Isaac Aligner and the Manta Structural variant caller.
Other genomics analysis tools such as the Starling small variant
caller, Strelka somatic variant caller, the Canvas copy number
caller, and Haplotype Compare for examining variant call sets will
be made available soon.
The current BaseSpace services will continue to be available
free to customers with 1 TB of cloud storage. BaseSpace
Professional and Enterprise will come with bioinformatics support
and will be available January 2016. For more information, visit the
BaseSpace blog.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow
@illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151001005517/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Mina
Nicoletti858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024